|
WO1996025925A1
(en)
*
|
1995-02-24 |
1996-08-29 |
Weg Stuart L |
Nasal and ocular administration of ketamine to manage pain and for detoxification
|
|
GB0009469D0
(en)
*
|
2000-04-17 |
2000-06-07 |
Vectura Ltd |
Improvements in or relating to formalities for use in inhaler devices
|
|
US20050148673A1
(en)
|
2002-07-11 |
2005-07-07 |
Harbut Ronald E. |
Prolonged administration of NMDA antagonist and safener drug to alter neuropathic pain condition
|
|
MXPA05000294A
(es)
|
2002-07-30 |
2005-08-19 |
Peter Migaly |
Terapia combinada para la depresion, prevencion de suicidios y varias condiciones medicas y psiquiatricas.
|
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
|
ATE432697T1
(de)
*
|
2002-11-18 |
2009-06-15 |
Yaupon Therapeutics Inc |
Analgetische verwendung von (s)-norketamin
|
|
US10172810B2
(en)
|
2003-02-24 |
2019-01-08 |
Pharmaceutical Productions, Inc. |
Transmucosal ketamine delivery composition
|
|
MXPA05009134A
(es)
|
2003-02-26 |
2005-12-05 |
Johns Hopkins Universty |
Compuestos y metodos moduladores del transporte del glutamato.
|
|
US20050038062A1
(en)
|
2003-04-14 |
2005-02-17 |
Burns Lindsay H. |
Methods and materials for the treatment of pain comprising opioid antagonists
|
|
MXPA06011891A
(es)
|
2004-04-20 |
2007-04-24 |
Pfizer |
Metodo para tratar el dolor neuropatico.
|
|
WO2006042249A2
(en)
|
2004-10-08 |
2006-04-20 |
Neuromolecular Pharmaceuticals, Inc. |
Methods and compositions for treating migraine pain
|
|
WO2006069293A2
(en)
|
2004-12-22 |
2006-06-29 |
Friedman Robert S |
Composition comprising n-acetylcysteine and further pain or anti- inflamm medications
|
|
BRPI0607402A2
(pt)
|
2005-03-01 |
2009-09-01 |
Pfizer Ltd |
uso de inibidores de pde7 para o tratamento de dor neuropática
|
|
CA2603913A1
(en)
|
2005-03-04 |
2006-09-14 |
Mentis Cura Ehf. |
A method and a system for assessing neurological conditions
|
|
MX2007012374A
(es)
|
2005-04-06 |
2008-02-22 |
Adamas Pharmaceuticals Inc |
Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
|
|
GB0523031D0
(en)
*
|
2005-11-11 |
2005-12-21 |
Yaupon Therapeutics |
Enhancement of morphine analgesia by s(-)-norketamine
|
|
CA2633070C
(en)
|
2005-12-19 |
2016-03-08 |
Pharmain Corporation |
Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
|
|
CN101466364A
(zh)
*
|
2006-03-22 |
2009-06-24 |
纽约大学西奈山医学院 |
鼻内施用氯胺酮治疗抑郁症
|
|
BRPI0711872A2
(pt)
|
2006-05-22 |
2011-12-06 |
Vanda Pharmaceuticals Inc |
tratamento para distúrbios depressivos
|
|
EP1902733A1
(en)
|
2006-09-19 |
2008-03-26 |
Laboratorios Del Dr. Esteve, S.A. |
Combination of a NMDA-receptor ligand and a compound with 5-HT6 receptor affinity
|
|
WO2009014770A2
(en)
|
2007-02-01 |
2009-01-29 |
Green Alan I |
Combinations of dopamine d2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade
|
|
DE102007009888A1
(de)
|
2007-02-28 |
2008-09-04 |
Hermann, Holger Lars, Dr. |
Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
|
|
DK2125698T3
(en)
|
2007-03-15 |
2016-11-07 |
Auspex Pharmaceuticals Inc |
Deuterated d9-VENLAFAXINE
|
|
US20080280886A1
(en)
|
2007-05-08 |
2008-11-13 |
Auspex Pharmaceuticals, Inc. |
Substituted ureas
|
|
US20090004281A1
(en)
|
2007-06-26 |
2009-01-01 |
Biovail Laboratories International S.R.L. |
Multiparticulate osmotic delivery system
|
|
EP2175886A1
(en)
|
2007-06-28 |
2010-04-21 |
CNSBio Pty Ltd |
Combination methods and compositions for treatment of neuropathic pain
|
|
EP2178584A2
(en)
|
2007-07-26 |
2010-04-28 |
Entra Pharmaceuticals Inc. |
Skin-patch pump comprising a changing-volume electrochemical actuator
|
|
US10300031B2
(en)
|
2007-08-06 |
2019-05-28 |
Trinity Laboratories Inc. |
Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
|
|
WO2009039460A2
(en)
|
2007-09-21 |
2009-03-26 |
Acadia Pharmaceuticals, Inc. |
Co-administration of pimavanserin with other agents
|
|
US20100297181A1
(en)
|
2007-12-26 |
2010-11-25 |
Eisai R&D Management Co., Ltd. |
AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
|
|
US20090198145A1
(en)
|
2008-02-06 |
2009-08-06 |
Chow Harrison |
Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep
|
|
US20140037718A1
(en)
|
2009-03-06 |
2014-02-06 |
George W. Lutz |
Transdermal pain gel
|
|
GB0908129D0
(en)
*
|
2009-05-12 |
2009-06-24 |
Innovata Ltd |
Composition
|
|
US20120225949A1
(en)
|
2009-08-14 |
2012-09-06 |
Demitri Papalos |
Compositions and methods for treating bipolar disorder
|
|
CA2777218C
(en)
|
2009-10-30 |
2016-09-27 |
Ix Biopharma Pte Ltd |
Fast dissolving solid dosage form
|
|
EP2526500A2
(en)
|
2010-01-18 |
2012-11-28 |
Elminda Ltd. |
Method and system for weighted analysis of neurophysiological data
|
|
WO2013003669A2
(en)
|
2011-06-30 |
2013-01-03 |
University Of South Florida |
Compositions, methods of use, and methods of treatment
|
|
JP2015501652A
(ja)
|
2011-12-14 |
2015-01-19 |
アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ |
Ｇａｂｒ−ａ２診断
|
|
KR20140136982A
(ko)
|
2012-03-12 |
2014-12-01 |
얀센 파마슈티카 엔.브이. |
치료-불응성 또는 치료-저항성 우울증 치료용 에스케타민
|
|
JP2015512418A
(ja)
|
2012-03-30 |
2015-04-27 |
ザ ジェネラル ホスピタル コーポレイション |
うつ病の治療におけるスコポラミンおよびケタミンを含む組成物
|
|
US20120323214A1
(en)
|
2012-05-16 |
2012-12-20 |
Totada R Shantha |
Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis
|
|
WO2014020155A1
(en)
|
2012-08-02 |
2014-02-06 |
Clinpharm Reform Gmbh |
Oral transmucosal adminstration forms of s-ketamine
|
|
US20140057988A1
(en)
|
2012-08-23 |
2014-02-27 |
Stuart WEG |
Anxiolytic composition, formulation and method of use
|
|
US8974365B2
(en)
|
2012-11-25 |
2015-03-10 |
Steven Richard Devore Best |
Treatment of thalamocortical dysrhythmia
|
|
JP6391120B2
(ja)
|
2012-12-20 |
2018-09-19 |
サンフォード−バーンハム メディカル リサーチ インスティテュート |
ニューロテンシン受容体１の小分子アゴニスト
|
|
CN116251084A
(zh)
|
2013-03-15 |
2023-06-13 |
詹森药业有限公司 |
S-盐酸氯胺酮的药物组合物
|
|
BR112015022972B1
(pt)
|
2013-03-15 |
2023-02-14 |
Janssen Pharmaceutica Nv |
Composição farmacêutica de cloridrato de s-cetamina e formas de dosagem da mesma
|
|
AU2014248455B2
(en)
*
|
2013-04-01 |
2018-12-06 |
Pulmatrix Operating Company, Inc. |
Tiotropium dry powders
|
|
US9913803B2
(en)
|
2013-08-26 |
2018-03-13 |
Amorsa Therapeutics, Inc. |
Single-layer oral dose of neuro-attenuating ketamine
|
|
WO2015037248A1
(en)
|
2013-09-13 |
2015-03-19 |
National University Corporation Chiba University |
Application of r-ketamine and salt thereof as pharmaceuticals
|
|
CA2936809A1
(en)
|
2014-01-14 |
2015-07-23 |
Children's Hospital Medical Center |
Compositions comprising ketamine for treating an autism spectrum disorder
|
|
HUE051264T2
(hu)
|
2014-04-17 |
2021-03-01 |
Develco Pharma Schweiz Ag |
Ketamin orális dózisformája
|
|
KR20170013890A
(ko)
|
2014-05-06 |
2017-02-07 |
노쓰웨스턴유니버시티 |
Nmdar 조절 화합물의 조합물
|
|
US11207316B2
(en)
|
2014-05-30 |
2021-12-28 |
West Virginia University |
Ketamine or dextromethorphan formulations and methods of use
|
|
US20160008777A1
(en)
|
2014-07-09 |
2016-01-14 |
Novotec Consulting Inc. |
Pharmaceutical compounding kit
|
|
JP6545788B2
(ja)
|
2014-08-13 |
2019-07-17 |
ヤンセン ファーマシューティカ エヌ．ベー． |
うつ病の治療方法
|
|
CN107208133A
(zh)
|
2014-09-15 |
2017-09-26 |
詹森药业有限公司 |
用于治疗抑郁症的Val66Met (SNPrs6265)基因型特异性给药方案和方法
|
|
CA2963085C
(en)
*
|
2014-10-07 |
2023-02-21 |
Lam Therapeutics, Inc. |
An inhalable rapamycin formulation for the treatment of pulmonary hypertension
|
|
CN115521217A
(zh)
|
2014-11-04 |
2022-12-27 |
阿莫萨治疗公司 |
神经衰减性氯胺酮和去甲氯胺酮化合物、其衍生物和方法
|
|
WO2016094358A1
(en)
|
2014-12-08 |
2016-06-16 |
Cima Labs Inc. |
Immediate release abuse-deterrent granulated dosage forms
|
|
US20180015054A1
(en)
|
2014-12-31 |
2018-01-18 |
Icahn School Of Medicine At Mount Sinai |
Method of Maintaining the Anti-Depressant Effect of Ketamine With Lithium
|
|
US10302625B2
(en)
|
2015-01-15 |
2019-05-28 |
Centre For Addiction And Mental Health |
Peripheral measure of central brain inflammation, markers therefor and uses thereof
|
|
EP3085366A1
(en)
|
2015-04-22 |
2016-10-26 |
Institut du Cerveau et de la Moelle Epiniere-ICM |
Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
|
|
US20160332962A1
(en)
*
|
2015-05-13 |
2016-11-17 |
Janssen Pharmaceutica Nv |
(s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
|
|
WO2016186968A1
(en)
|
2015-05-15 |
2016-11-24 |
The Arizona Board Of Regents On Behalf Of The University Of Arizona |
Compositions and methods for treating motor disorders
|
|
US20160338977A1
(en)
|
2015-05-20 |
2016-11-24 |
Janssen Pharmaceutica Nv |
Methods and kits for treating depression
|
|
WO2016201299A1
(en)
|
2015-06-12 |
2016-12-15 |
Indiana University Research & Technology Corporation |
Predicting suicidality using a combined genomic and clinical risk assessment
|
|
HK1248578A1
(zh)
|
2015-06-27 |
2018-10-19 |
Shenox Pharmaceuticals, Llc |
氯胺酮透皮递送系统
|
|
CN106562952B
(zh)
*
|
2015-10-09 |
2020-06-09 |
江阴安博生物医药有限公司 |
氯胺酮在治疗重性抑郁障碍中的应用
|
|
CN108601814A
(zh)
|
2015-10-16 |
2018-09-28 |
西北大学 |
用于治疗精神分裂症、双相障碍、认知损害和重度抑郁障碍的非典型抗精神病药和nmda调节剂的药物组合
|
|
US11110070B2
(en)
|
2015-11-17 |
2021-09-07 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
|
|
US10881637B2
(en)
|
2015-11-17 |
2021-01-05 |
Atlee Solomon |
Intranasal and transdermal administration of kappa-opioid-receptor agonists: salvinorin A for the treatment of neuropsychiatric and addictive disorders
|
|
US20180296478A1
(en)
|
2016-02-12 |
2018-10-18 |
Synergistic Therapeutics, Llc |
Sublingual antidepressant and antianxiety tablet
|
|
US20180042936A1
(en)
|
2016-03-18 |
2018-02-15 |
Genomind, Inc. |
Maintenance therapy using tianeptine
|
|
JP2019512528A
(ja)
|
2016-03-25 |
2019-05-16 |
ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
抑うつ、不安症、快感消失症、疲労、自殺念慮、および外傷後ストレス障害の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミンおよび（２ｓ，６ｓ）−ヒドロキシノルケタミンの使用方法
|
|
JP6967532B2
(ja)
|
2016-05-25 |
2021-11-17 |
ナショナル ヘルス リサーチ インスティテューツNational Health Research Institutes |
付加的抗うつ剤組成物及びその使用方法
|
|
KR20240027874A
(ko)
|
2016-07-28 |
2024-03-04 |
리제너론 파마슈티칼스 인코포레이티드 |
Gpr156 변이체 및 이들의 용도
|
|
JP2019527703A
(ja)
|
2016-08-05 |
2019-10-03 |
株式会社新日本科学 |
鼻腔内薬学的粉末組成物
|
|
US20180064655A1
(en)
|
2016-09-06 |
2018-03-08 |
Steven Sounyoung Yu |
Hydroxynorketamine Transdermal Patch
|
|
US10596378B2
(en)
|
2016-10-18 |
2020-03-24 |
Joseph Rustick |
Method for treatment of depression using synaptic pathway training
|
|
US10905897B2
(en)
|
2016-10-20 |
2021-02-02 |
Neuro-Laser Foundation, Inc. |
Synergistic treatment methodologies using light therapy
|
|
JPWO2018079693A1
(ja)
|
2016-10-27 |
2019-10-31 |
国立大学法人千葉大学 |
（ｓ）−ノルケタミンおよびその塩の医薬品としての応用
|
|
US20180177744A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain and depression using a hybrid mixture of s-ketamine and r-ketamine
|
|
US20180177743A1
(en)
|
2016-12-22 |
2018-06-28 |
Gary Jay |
Method of treating pain using racemic mixture of s-ketamine and r-ketamine
|
|
CN110913844A
(zh)
|
2017-04-20 |
2020-03-24 |
广州大洲生物医药科技有限公司 |
用于氯胺酮的透皮药物递送系统
|
|
WO2018209341A1
(en)
|
2017-05-12 |
2018-11-15 |
Indiana University Research And Technology Corporation |
Precision medicine for treating and preventing suicidality
|
|
CN110996946A
(zh)
|
2017-05-25 |
2020-04-10 |
格莱泰施有限责任公司 |
用于治疗创伤后应激障碍的制剂
|
|
DE102017112527B4
(de)
|
2017-06-07 |
2019-01-03 |
Lts Lohmann Therapie-Systeme Ag |
Schnell zerfallende Schaumwafer mit hohem Flächengewicht
|
|
EP3641742A2
(en)
|
2017-06-23 |
2020-04-29 |
Develco Pharma Schweiz AG |
Hydroxynorketamine for the use in the treatment of depression
|
|
CN110996912A
(zh)
|
2017-08-20 |
2020-04-10 |
福摩莱克斯医药创新有限公司 |
用于鼻内递送的干粉组合物
|
|
US20210315840A1
(en)
|
2017-09-25 |
2021-10-14 |
Small Pharma Ltd |
Solid oral dosage forms of ketamine derivatives
|
|
US20200405663A1
(en)
|
2017-09-27 |
2020-12-31 |
National University Corporation Chiba University |
R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition functional disorder
|
|
US12090123B2
(en)
|
2017-10-10 |
2024-09-17 |
Douglas Pharmaceuticals Ltd. |
Extended release pharmaceutical formulation
|
|
EP3698260A4
(en)
|
2017-10-19 |
2021-08-04 |
Eleusis Health Solutions US, Inc. |
METHODS AND SYSTEMS FOR INCREASING THE SAFETY OF AWARENESS-ENHANCING DRUG THERAPIES
|
|
WO2019094757A1
(en)
|
2017-11-09 |
2019-05-16 |
The Trustees Of Columbia University In The City Of New York |
Pharmacological prophylactics against stress-induced affective disorders in females
|
|
CA3082423A1
(en)
|
2017-11-14 |
2019-05-23 |
Bexson Biomedical, Inc. |
Systems, devices, formulations and methods for controlled drug delivery
|
|
DE102017129012A1
(de)
|
2017-12-06 |
2019-06-06 |
Lts Lohmann Therapie-Systeme Ag |
Oraler Dünnfilm mit hoher Wirkstoffbeladung
|
|
CN112423789A
(zh)
|
2017-12-22 |
2021-02-26 |
詹森药业有限公司 |
用于治疗抑郁症的艾司氯胺酮
|
|
EP3505157B1
(en)
|
2017-12-29 |
2021-12-08 |
Celon Pharma S.A. |
Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
|
|
MX2020007479A
(es)
|
2018-01-10 |
2020-11-24 |
Xwpharma Ltd |
Profármacos de ketamina, composiciones y usos de los mismos.
|
|
JP7354123B2
(ja)
|
2018-02-21 |
2023-10-02 |
エイアイ・セラピューティクス・インコーポレーテッド |
アピリモドとグルタミン酸作動薬を用いた併用療法
|
|
EP3765021A4
(en)
|
2018-03-16 |
2022-03-09 |
Intra-Cellular Therapies, Inc. |
NOVEL PROCESSES
|
|
EP3761970A4
(en)
|
2018-03-26 |
2022-06-08 |
Cellix Bio Private Limited |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
|
|
US20230390385A1
(en)
|
2018-04-11 |
2023-12-07 |
Fred M. COWAN |
Compositions and Methods for Prevention and Treatment of Immune Complex Disease
|
|
US11426367B2
(en)
|
2018-05-04 |
2022-08-30 |
Perception Neuroscience, Inc. |
Methods of treating substance abuse
|
|
US11766409B2
(en)
|
2018-05-31 |
2023-09-26 |
The University Of Queensland |
Core-shell polymer nanoparticle
|
|
GB201809976D0
(en)
|
2018-06-18 |
2018-08-01 |
Neurocentrx Pharma Ltd |
Novel formulations
|
|
EP3813807A1
(en)
|
2018-06-27 |
2021-05-05 |
Clexio Biosciences Ltd. |
Method of treating major depressive disorder
|
|
WO2020006092A1
(en)
|
2018-06-27 |
2020-01-02 |
Bioxcel Therapeutics, Inc. |
Film formulations containing dexmedetomidine and methods of producing them
|
|
WO2020028475A1
(en)
|
2018-08-02 |
2020-02-06 |
Taiwan Liposome Co., Ltd. |
Sustained-release compositions comprising a therapeutic agent for treating depression or anxiety and uses thereof
|
|
US20200038420A1
(en)
|
2018-08-03 |
2020-02-06 |
Enterin, Inc. |
Aminosterol compositions and methods of using the same for treating depression
|
|
US11154537B2
(en)
|
2018-08-10 |
2021-10-26 |
Eleusis Therapeutics Us, Inc. |
Method of treatment for ketamine infusion
|
|
US12090145B2
(en)
|
2018-08-20 |
2024-09-17 |
Yale University |
Combination therapy for treating or preventing depression or other mood diseases
|
|
PL3628313T3
(pl)
*
|
2018-09-28 |
2025-06-23 |
Novohale Therapeutics, Llc |
Kompozycja ketaminy do zastosowania w sposobie leczenia depresji przez podawanie dopłucne
|
|
US20210113494A1
(en)
|
2018-10-05 |
2021-04-22 |
Clexio Biosciences Ltd. |
Method Of Treating Post-Traumatic Stress Syndrome
|
|
WO2020086673A1
(en)
|
2018-10-26 |
2020-04-30 |
Guangzhou Dazhou Biomedicine Ltd. |
Ketamine oral transmucosal delivery system
|
|
WO2020089897A1
(en)
|
2018-10-29 |
2020-05-07 |
Hadasit Medical Research Services & Development Limited |
Combination of m-opioid receptor (mor) modulators for preventing and treating pain, suicidality and mental disorders
|
|
WO2020106927A1
(en)
|
2018-11-21 |
2020-05-28 |
Certego Therapeutics |
Gaboxadol for reducing risk of suicide and rapid relief of depression
|
|
HUE065684T2
(hu)
|
2019-01-11 |
2024-06-28 |
Alar Pharmaceuticals Inc |
Ketamin-pamoát és alkalmazása
|
|
EP3915121A1
(en)
|
2019-01-23 |
2021-12-01 |
The Regents Of The University Of Michigan |
Methods and system for the reconstruction of drug response and disease networks and uses thereof
|
|
US20200261422A1
(en)
|
2019-02-15 |
2020-08-20 |
Massachusetts Institute Of Technology |
Methods for evaluating treatments and physiology in human patients using intravenous alpha-2 adrenergic antagonist agents
|
|
JP2022524008A
(ja)
|
2019-03-05 |
2022-04-27 |
ヤンセン ファーマシューティカルズ，インコーポレーテッド |
うつ病の治療のためのエスケタミン
|
|
EP3934633A4
(en)
|
2019-03-07 |
2023-03-29 |
Arbormentis LLC |
COMPOSITIONS AND METHODS OF USE WITH SUBSTANCES WITH NEURAL PLASTIC EFFECTS ADMINISTRATED IN NON-PSYCHEDELIC/PSYCHOTOMIMETIC DOSES AND FORMULATIONS
|
|
WO2020190997A1
(en)
|
2019-03-18 |
2020-09-24 |
New York Medical College |
Intranasal neuropeptides for use in stress-related impairments
|
|
CA3135552C
(en)
|
2019-04-17 |
2023-09-26 |
Lts Lohmann Therapie-Systeme Ag |
Ketamine containing transdermal therapeutic system comprising free hydroxyl groups
|
|
WO2020223701A1
(en)
|
2019-05-02 |
2020-11-05 |
The Broad Institute, Inc. |
Methods for treating neurodevelopmental disorders
|
|
US20220202742A1
(en)
|
2019-05-07 |
2022-06-30 |
Clexio Biosciences Ltd. |
Dosage forms for preventing drug-facilitated assault
|
|
US20220062200A1
(en)
|
2019-05-07 |
2022-03-03 |
Clexio Biosciences Ltd. |
Abuse-deterrent dosage forms containing esketamine
|
|
KR20220012922A
(ko)
|
2019-05-31 |
2022-02-04 |
셀론 파르마 에스.에이. |
약학적 조성물의 전자적으로 관리된 투여
|
|
CN113905777B
(zh)
|
2019-05-31 |
2025-06-20 |
赛隆制药股份公司 |
用于电子监督胃肠外施用药物组合物的吸入器
|
|
US12502363B2
(en)
|
2019-06-04 |
2025-12-23 |
ADNP Kids Research Foundation |
Ketamine and ketamine/nap for treatment of ADNP syndrome and related neurological conditions
|
|
US20220151955A1
(en)
|
2019-08-05 |
2022-05-19 |
The Ketamine Research Foundation |
Ketamine for the treatment of postpartum symptoms and disorders
|
|
EP4021432A4
(en)
|
2019-08-28 |
2023-08-16 |
Janssen Pharmaceuticals, Inc. |
ESKETAMIN FOR THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER, INCLUDING SUICIDALITY
|
|
GB201912505D0
(en)
|
2019-08-30 |
2019-10-16 |
Klaria Pharma Holding Ab |
Pharmaceutical formulation
|
|
CA3153856A1
(en)
|
2019-09-13 |
2021-03-18 |
Janssen Pharmaceuticals, Inc. |
Intranasal administration of esketamine
|
|
EP4041226A1
(en)
|
2019-10-02 |
2022-08-17 |
Praxis Precision Medicines, Inc. |
Combinations of gaba-a receptor positive allosteric modulators and nmda antagonists, nmda negative allosteric modulators or nmda partial agonists
|
|
EP4497471A3
(en)
|
2019-10-18 |
2025-03-12 |
Institute of Science and Technology Austria |
Stimulation of neuronal plasticity
|
|
US20220378777A1
(en)
|
2019-10-31 |
2022-12-01 |
The Trustees Of Indiana University |
Compositions and methods for treating alcohol use disorder or a related condition thereof
|
|
US20220401366A1
(en)
|
2019-11-15 |
2022-12-22 |
Consegna Pharma, Inc. |
Long acting nmda antagonists
|
|
WO2021101867A1
(en)
|
2019-11-18 |
2021-05-27 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Salts of (2r, 6r)-hydroxynorketamine, their crystal forms, and methods of making the same
|
|
US11660305B2
(en)
|
2019-11-19 |
2023-05-30 |
Turtle Bear Holdings, Llc |
Tryptamine compositions for enhancing neurite outgrowth
|
|
TW202135787A
(zh)
|
2019-12-12 |
2021-10-01 |
比利時商健生藥品公司 |
艾氯胺酮調配物及製備與儲存的方法
|
|
RS67418B1
(sr)
|
2019-12-20 |
2025-12-31 |
Alar Pharmaceuticals Inc |
Injekcione formulacije pamoatnih soli ketamina sa dugotrajnim dejstvom
|
|
JP2023507926A
(ja)
|
2019-12-30 |
2023-02-28 |
クレキシオ バイオサイエンシーズ エルティーディー． |
神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画
|
|
IL293506A
(en)
|
2019-12-30 |
2022-08-01 |
Clexio Biosciences Ltd |
Dosage regime with esketamine for treating major depressive disorder
|
|
MX2022009050A
(es)
|
2020-01-22 |
2022-10-27 |
Seelos Therapeutics Inc |
Reduccion de los efectos secundarios de los antagonistas de nmda.
|
|
DE102020106115A1
(de)
|
2020-03-06 |
2021-09-09 |
Lts Lohmann Therapie-Systeme Ag |
Iontophoretische Zusammensetzung zur Verabreichung von S-Ketamin
|
|
WO2021207349A1
(en)
|
2020-04-07 |
2021-10-14 |
Joseph Habboushe |
Prevention and treatment of virial infections
|
|
IL298334A
(en)
|
2020-05-20 |
2023-01-01 |
Certego Therapeutics Inc |
Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
|
|
US20230210789A1
(en)
|
2020-06-02 |
2023-07-06 |
Ix Biopharma Limited |
Methods for treating major depressive disorder and treatment-resistant depression
|
|
TW202214218A
(zh)
|
2020-06-19 |
2022-04-16 |
大陸商廣州大洲生物醫藥科技有限公司 |
氯胺酮的透皮給藥系統
|
|
US20210401774A1
(en)
|
2020-06-27 |
2021-12-30 |
Robert Brent Turnipseed |
Ketamine protocols and data evaluation for treatment-resistant depression and trauma
|
|
US20220001014A1
(en)
|
2020-07-01 |
2022-01-06 |
Lida Ghaderi |
Compositions and methods for inducing biological mimicry in a mammal for the prevention and/or treatment of covid-19 and other diseases
|
|
US20220040106A1
(en)
|
2020-08-05 |
2022-02-10 |
Thomas Malcolm |
Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
|
|
EP3949956A1
(en)
|
2020-08-06 |
2022-02-09 |
LTS Lohmann Therapie-Systeme AG |
Esketamine-suspension-tts
|
|
JP2023538901A
(ja)
|
2020-08-18 |
2023-09-12 |
オークウッド ラボラトリーズ，エル．エル．シー． |
ケタミンを含むマイクロスフェア製剤ならびにその製造及び使用方法
|
|
WO2022081350A2
(en)
|
2020-09-30 |
2022-04-21 |
Duke University |
Methods for identification, stratification, and treatment of cns diseases
|
|
AU2021374831B2
(en)
|
2020-11-09 |
2024-08-01 |
Lts Lohmann Therapie-Systeme Ag |
Oral thin film
|
|
US20230420110A1
(en)
|
2020-11-18 |
2023-12-28 |
Indiana University Research And Technology Corporation |
Methods for objective assessment, risk prediction, matching to existing medications and new methods of using drugs, and monitoring responses to treatments for mood disorders
|
|
US11382873B1
(en)
|
2021-01-08 |
2022-07-12 |
Vitalis Analgesics LLC |
Oral administration of ketamine
|
|
IL282188A
(en)
|
2021-04-08 |
2022-11-01 |
Yeda Res & Dev |
Combined use of ketamine and bretigabine for the treatment of psychiatric disorders
|
|
KR20240027792A
(ko)
|
2021-08-13 |
2024-03-04 |
엑스더블유파마 리미티드 |
케타민 유도체의 약제학적 조성물 및 경구 투여 형태
|
|
US20230144704A1
(en)
|
2021-11-05 |
2023-05-11 |
Thomas Malcolm |
Tailored hypoimmune nanovesicular delivery systems for cancer tumors, hereditary and infectious diseases
|
|
US20240009145A1
(en)
|
2022-07-07 |
2024-01-11 |
Vitalis Analgesics LLC |
Compositions of aspirin and ketamine
|